Product news

Share this article:
Schering-Plough said the FDA has approved label revisions for Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of Rebetol (800-1400 mg daily) based on patient body weight. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus genotype 2 or 3.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.